Similar articles

• [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].

  Sarateanu DE, Ehrengut W. Sarateanu DE, et al. Fortschr Med. 1981 Sep 10;99(34):1348-52. Fortschr Med. 1981. PMID: 7026399 Clinical Trial. German. No abstract available.
• NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. I. DEVELOPMENT AND ANIMAL IMMUNE RESPONSE.

  WOODHOUR AF, METZGAR DP, STIM TB, TYTELL AA, HILLEMAN MR. WOODHOUR AF, et al. Proc Soc Exp Biol Med. 1964 Jun;116:516-23. doi: 10.3181/00379727-116-29295. Proc Soc Exp Biol Med. 1964. PMID: 14193390 No abstract available.
• FIELD TRIALS OF ADJUVANT AND SALINE INFLUENZA VACCINES.

  HERBERT WJ, SELWYN S, PHILP JR. HERBERT WJ, et al. Br J Prev Soc Med. 1965 Apr;19(2):97-100. doi: 10.1136/jech.19.2.97. Br J Prev Soc Med. 1965. PMID: 14319217 Free PMC article. No abstract available.
• MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

  El Sahly H. El Sahly H. Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Expert Rev Vaccines. 2010. PMID: 20923265 Review.
• Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

  Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Burt D, et al. Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Expert Rev Vaccines. 2011. PMID: 21434804 Review.